1) Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history
2) Treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy
Limitation of use: Eculizumab is not indicated for the treatment of patients with Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome.
3) Treatment of refractory generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive